Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Cumulative Review of Hypertension in Patients with Chronic Lymphocytic Leukemia (CLL) and Other Hematologic Malignancies Treated with Acalabrutinib

Alessandra Ferrajoli, George Follows, Yotvat Marmor, Shogheeg Apkarian Bourjlian, Jack Roos, Naghmana Bajwa, Venkata Madhira, Kenji Nozaki, Paulo Andre P. Palhares De Miranda, Krish Patel

Blood (2023) 142 (Supplement 1): 1917.

https://doi.org/10.1182/blood-2023-174727

Published: 2023

Journal Articles

Acrue: A Phase 2, Open-Label Study of Acalabrutinib in Combination with Rituximab in Elderly and/or Frail Patients with Treatment-Naive Diffuse Large B-Cell Lymphoma

Guilherme F Perini, Tara Graff, Jack Roos, Richard Hermann, Magnus Lovenklev, Bob Shaw, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 6246.

https://doi.org/10.1182/blood-2023-174769

Published: 2023

Journal Articles

A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia

John N. Allan, Adam S Kittai, Dan James, Helen Ridge, Miguel Miranda, Alan Yong, Fady Fam, Jack Roos, Vikram Shetty, Matthew S. Davids, Alan Skarbnik

Blood (2023) 142 (Supplement 1): 6563.

https://doi.org/10.1182/blood-2023-178698

Published: 2023

Journal Articles

Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Priyanka Gaitonde, Ling Cai, Paulo de Miranda, Jack Roos, Simon Rule, Michael L. Wang

Blood (2022) 140 (Supplement 1): 3646–3647.

https://doi.org/10.1182/blood-2022-169661

Published: 2022